Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia

被引:15
作者
Chong, T
Naples, M
Federico, L
Taylor, D
Smith, GJ
Cheung, RC
Adeli, K
机构
[1] Hosp Sick Children, Res Inst, Div Clin Biochem, Toronto, ON M5G 1X8, Canada
[2] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada
[3] Univ Windsor, Windsor, ON N9B 3B4, Canada
[4] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England
关键词
apolipoprotein B; rosuvastatin; insulin resistance; syrian golden hamster; HMG-CoA reductase; insulin receptor; microsomal triglyceride transfer protein;
D O I
10.1016/j.atherosclerosis.2005.05.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A novel animal model of insulin resistance, the fructose-fed Syrian golden hamster, was employed to investigate the efficacy and mechanisms of action of rosuvastatin, a HMG-CoA reductase inhibitor, in ameliorating metabolic dyslipidemia in insulin-resistant states. Fructose feeding for a 2-week period induced insulin resistance and a significant increase in hepatic secretion of VLDL. This was followed by a fructose-enriched diet with or without 10 mg/kg rosuvastatin for 14 days. Fructose feeding in the first 2 weeks caused a significant increase in plasma total cholesterol and triglyceride in both groups (n = 6, p < 0.001). However, there was a significant decline (30%, n = 8, p < 0.05) in plasma triglyceride levels following rosuvastatin feeding (10 mg/kg). A significant decrease (n = 6, p < 0.05) was also observed in VLDL-apoB production in hepatocytes isolated from drug-treated hamsters, together with an increased apoB degradation (n = 6, p < 0.05). Similar results were obtained in parallel cell culture experiments in which primary hepatocytes were first isolated from chow-fed hamsters, and then treated in vitro with 15 mu M rosuvastatin for 18 h. Rosuvastatin at 5 mu M caused a substantial reduction in synthesis of unesterified cholesterol and cholesterol ester (98 and 25%, n = 9, p < 0.01 or p < 0.05) and secretion of newly synthesized unesterified cholesterol, cholesterol ester, and triglyceride (95, 42, and 60% reduction, respectively, n = 9, p < 0.01 or p < 0.05). This concentration of rosuvastatin also caused a significant reduction (75% decrease, n = 4, p < 0.01) in the extracellular secretion of VLDL-apoB100, accompanied by a significant increase in the intracellular degradation of apoB 100. There was a 12% reduction (not significant, p > 0.05) in hepatic MTP and no changes in ER-60 (a chaperone involved in apoB degradation) protein levels. Taken together, these data suggest that the assembly and secretion of VLDL particles in hamster hepatocytes can be acutely inhibited by rosuvastatin in a process involving enhanced apoB degradation. This appears to lead to a significant amelioration of hepatic VLDL-apoB overproduction observed in the fructose-fed, insulin-resistant hamster model. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:21 / 31
页数:11
相关论文
共 39 条
[1]   Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance [J].
Adeli, K ;
Taghibiglou, C ;
Van Iderstine, SC ;
Lewis, GF .
TRENDS IN CARDIOVASCULAR MEDICINE, 2001, 11 (05) :170-176
[2]   Apolipoprotein B is intracellularly associated with an ER-60 protease homologue in HepG2 cells [J].
Adeli, K ;
Macri, J ;
Mohammadi, A ;
Kito, M ;
Urade, R ;
Cavallo, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (36) :22489-22494
[3]   Mechanisms of metabolic dyslipidemia in insulin resistant states: Deregulation of hepatic and intestinal lipoprotein secretion [J].
Avramoglu, RK ;
Qiu, W ;
Adeli, K .
FRONTIERS IN BIOSCIENCE, 2003, 8 :D464-D476
[4]   Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome [J].
Ballantyne, CM ;
Stein, EA ;
Paoletti, R ;
Southworth, H ;
Blasetto, JW .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (5A) :25C-27C
[5]   Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups [J].
Blasetto, JW ;
Stein, EA ;
Brown, WV ;
Chitra, R ;
Raza, A .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 91 (5A) :3C-10C
[6]  
BRIGGS MR, 1993, J BIOL CHEM, V268, P14490
[7]   The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs [J].
Burnett, JR ;
Wilcox, LJ ;
Telford, DE ;
Kleinstiver, SJ ;
Barrett, PHR ;
Newton, RS ;
Huff, MW .
ENDOCRINOLOGY, 1999, 140 (11) :5293-5302
[8]   Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster [J].
Carpentier, A ;
Taghibiglou, C ;
Leung, N ;
Szeto, L ;
Van Iderstine, SC ;
Uffelman, KD ;
Buckingham, R ;
Adeli, K ;
Lewis, GF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (32) :28795-28802
[9]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[10]   RELATIONSHIP BETWEEN LIPOPROTEIN LEVELS AND INVIVO INSULIN ACTION IN NORMAL YOUNG WHITE MEN [J].
GARG, A ;
HELDERMAN, JH ;
KOFFLER, M ;
AYUSO, R ;
ROSENSTOCK, J ;
RASKIN, P .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1988, 37 (10) :982-987